Intellia Therapeutics Head office building


Frank Verwiel, M.D.


Frank Verwiel brings more than 25 years of strategic, operational and international experience in the biotech and pharmaceutical industry to Intellia’s Board of Directors. Frank currently serves as chairman of the board of directors of ObsEva SA, a biopharmaceutical company focused on women’s reproductive health. He also holds membership and committee chair positions on the boards of AveXis, Inc. (NASDAQ: AVXS), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Bavarian Nordic A/S (CPH: BAVA). Previously, he served on the board of directors of the Biotechnology Industry Organization.

Frank possesses significant biotech and pharmaceutical experience, having been the President and CEO of Aptalis Pharma Inc., prior to its acquisition in 2014 by Forest Laboratories. Frank also led the global hypertension franchise at Merck & Co. and served as the general manager of Merck Sharpe Dohme’s operations in the Netherlands and held numerous leadership positions in the commercial organization at Servier Laboratories.

Frank received a doctorate in medicine from Erasmus University in Rotterdam, Netherlands. He received his MBA from the Institut Européen d’Administration des Affaires (INSEAD) in Fontainebleau, France.

Independent Director